MaxCyte (NASDAQ:MXCT) Issues Earnings Results

by · The Markets Daily

MaxCyte (NASDAQ:MXCT – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01, FiscalAI reports. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The business had revenue of $6.50 million for the quarter, compared to the consensus estimate of $6.51 million.

Here are the key takeaways from MaxCyte’s conference call:

  • MaxCyte reiterated its 2026 revenue guidance of $30 million–$32 million, with low single-digit year-over-year growth expected in the second half as instrument placements recover and prior inventory and partner-program headwinds subside.
  • The new enterprise-level Genentech partnership provides access to MaxCyte’s ExPERT GTx, electroporation, and SeQure technologies across multiple programs and development stages, potentially creating recurring license, platform-use, instrument, consumables, and milestone revenue.
  • Commercial momentum for Vertex’s CASGEVY continued, with approximately $76 million in second-quarter sales and more than 100 patient treatment initiations; MaxCyte’s SPL-related revenue rose to $0.8 million from $0.3 million a year earlier.
  • Management reported broad stabilization in instrument and processing-assembly demand, early traction for the DTx platform, and expects instrument revenue to be the primary growth driver in the second half; it also sees potential commercial launches from five partner programs over the next few years, mainly in 2027.
  • Second-quarter revenue declined 15% year over year to $7.3 million, while core revenue fell 21%; gross margin also decreased to 77% from 82% and is expected to remain in the mid-70% range as instrument revenue represents a larger mix.

MaxCyte Stock Performance

MXCT stock traded up $0.03 during trading on Wednesday, hitting $1.27. 1,896,727 shares of the company traded hands, compared to its average volume of 1,105,043. The company has a 50-day moving average of $1.19 and a 200-day moving average of $0.98. MaxCyte has a 1 year low of $0.64 and a 1 year high of $1.86. The firm has a market capitalization of $136.04 million, a PE ratio of -3.43 and a beta of 1.48.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MXCT shares. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.00.

View Our Latest Research Report on MXCT

Institutional Trading of MaxCyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new stake in MaxCyte in the second quarter worth $26,000. State of Wyoming purchased a new position in shares of MaxCyte during the second quarter valued at approximately $38,000. Jain Global LLC bought a new stake in MaxCyte in the fourth quarter worth $45,000. BNP Paribas Financial Markets raised its position in shares of MaxCyte by 266.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock worth $57,000 after purchasing an additional 18,913 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of MaxCyte in the 4th quarter worth about $67,000. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

(Get Free Report)

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.

See Also